# US 2019/0054170 A1 · Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054170 A1
- Document ID: US20190054170A1
- Status: Published application
- Kind: A1
- Application number: 16/143,889
- Filed: 2018-09-27
- Published: 2019-02-21
- Earliest claimed: 2016-03-30
- Inventors: Horst Lindhofer; Hartwig-Wilhelm Bauer
- Web page: https://patentgrep.com/patent/US20190054170A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/001113: {CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2}
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/31: multispecific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a multispecific antibody, or an antigen binding fragment thereof, for use in the treatment of a neoplasm of the urinary tract, in particular for the treatment of bladder cancer. Moreover, the present invention provides a pharmaceutical composition and a kit comprising such an antibody.

## Claims

### Claim 1

A method for treating a subject suffering from a neoplasm of the urinary tract, the method comprising:
administering to the subject a multispecific antibody, or an antigen binding fragment thereof, comprising:
a specificity against a T cell surface antigen, and
a specificity against a cancer-associated antigen or a tumor-associated antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, is administered systemically or locally into the urinary tract.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, is administered intravesically.

### Claim 4 (depends on 1)

The method of claim 1, wherein the neoplasm of the urinary tract is a neoplasm of the urothelium, preferably urothelial cell carcinoma.

### Claim 5 (depends on 1)

The method of claim 1, wherein the neoplasm of the urinary tract is a neoplasm of the lower urinary tract.

### Claim 6 (depends on 5)

The method of claim 5, wherein the neoplasm of the lower urinary tract is a neoplasm of the urinary bladder, preferably a carcinoma in situ of the urinary bladder or a malignant neoplasm of the urinary bladder.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neoplasm of the urinary bladder is carcinoma in situ of the urinary bladder, a non-muscular invasive urothelial cancer, or a muscular invasive urothelial cancer.

### Claim 8 (depends on 6)

The method of claim 6, wherein the neoplasm of the urinary bladder is a transitional cell carcinoma, a squamous cell carcinoma, an adenocarcinoma, a sarcoma, a small cell carcinoma, or a secondary deposit from a cancer elsewhere in the body.

### Claim 9 (depends on 1)

The method of claim 1, wherein the T cell surface antigen is CD2, CD3, CD4, CD5, CD6, CD8, CD28, CD40L, or CD44.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer-associated antigen or the tumor-associated antigen is EpCAM, HER2/neu, CEA, MAGE, proteoglycan, VEGF, EGFR, mTOR, PIK3CA, RAS, alpha(v)beta(3)-integrin, HLA, HLA-DR, ASC, carbonic anhydrase, CD1, CD2, CD4, CD6, CD7, CD8, CD11, CD13, CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD30 CD33, CD37, CD38, CD40, CD41, CD47, CD52, CD133, c-erb-2, CALLA, MHCII, CD44v3, CD44v6, p97, GM1, GM2, GM3, GD1a, GD1b, GD2, GD3, GT1b, GT3, GQ1, NY-ESO-1, NFX2, SSX2, SSX4, Trp2, gp100, tyrosinase, MUC-1, telomerase, survivin, p53, PD-L1, CA125, Wue antigen, Lewis Y antigen, HSP-27, HSP-70, HSP-72, HSP-90, Pgp, MCSP, EphA2, GC182, GT468, or GT512.

### Claim 11 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises two specificities selected from anti-EpCAM×anti-CD3, anti-CD20×anti-CD3, anti-HER2/neu×anti-CD3, anti-GD2×anti-CD3, and anti-CD19×anti-CD3.

### Claim 12 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, comprises an Fc moiety.

### Claim 13 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, is catumaxomab, FBTA05, ertumaxomab, ektomab, blinatumomab, or solitomab.

### Claim 14 (depends on 1)

The method of claim 1, wherein one treatment cycle comprises one initial dose and at least one subsequent dose; and
wherein the one initial dose and at least one subsequent dose is the same, or
wherein at least one subsequent dose is higher than the initial dose.

### Claim 15 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, is administered at a dose in a range of 0.1 μg to 5000 μg.

### Claim 16 (depends on 14)

The method of claim 14, wherein the initial dose of the antibody, or the antigen binding fragment thereof, is in a range of 0.5 μg to 500 μg.

### Claim 17 (depends on 16)

The method of claim 16, wherein the at least one subsequent dose comprises a first subsequent dose that exceeds the amount administered as initial dose by a factor of 1.1 to 10.0.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, is administered as stand-alone therapy.

### Claim 19 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, is administered in combination with autologous immune effector cells.

### Claim 20 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof, is administered in combination with an anti-cancer drug.

### Claim 21 (depends on 1)

The method of claim 1, wherein the antibody, or the antigen binding fragment thereof is provided in a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or vehicle.

### Claim 22 (depends on 21)

The method of claim 21, wherein the pharmaceutical comprises a buffer.

### Claim 23

A kit comprising:
a multispecific antibody, or an antigen binding fragment thereof, comprising:
a specificity against a T cell surface antigen, and
a specificity against a cancer-associated antigen or a tumor-associated antigen; and
a package insert or label with directions to treat a neoplasm of the urinary tract.
